Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Women and Lung Cancer Research and Preventive Services Act of 2025
Client: DAIICHI SANKYO INC · Firm: DAIICHI SANKYO, INC.
Discussions regarding H.R.946, the ORPHAN Cures Act Discussions related to H.R.2319, the Women and Lung Cancer Research and Preventative Services Act Discussions regarding H.R.4299,the Protecting Patient Access to Cancer and Complex Therapies Act Issues related to most-favored-nation and other foreign reference drug pricing policy Issues related to the Food and Drug Administration Issues regarding 340B program Issues related to utilization management of medications
Women and Lung Cancer Research and Preventive Services Act of 2025
Client: DAIICHI SANKYO INC · Firm: DAIICHI SANKYO, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2026 · third_quarter · Q3
Discussions regarding H.R.946, the ORPHAN Cures Act Discussions related to H.R.2319, the Women and Lung Cancer Research and Preventative Services Act Discussions regarding H.R.4299,the Protecting Patient Access to Cancer and Complex Therapies Act Issues related to most-favored-nation and other foreign reference drug pricing policy Issues related to the Food and Drug Administration Issues regarding 340B program Issues related to utilization management of medications
Issues related to the Medicare Drug Price Negotiation Program Issues regarding the GLOBE model
Source: Senate LDA
Discussions regarding H.R.946, the ORPHAN Cures Act Discussions related to H.R.2319, the Women and Lung Cancer Research and Preventative Services Act Discussions related to the Protecting Patient Access to Cancer and Complex Therapies Act reintroduction Issues related to most-favored-nation and other foreign reference drug pricing policy Issues related to the Food and Drug Administration Issues regarding 340B program
Protecting Patient Access to Cancer and Complex Therapies Act
Client: DAIICHI SANKYO INC · Firm: DAIICHI SANKYO, INC.
Discussions regarding H.R.946, the ORPHAN Cures Act Discussions related to H.R.2319, the Women and Lung Cancer Research and Preventative Services Act Discussions regarding H.R.4299,the Protecting Patient Access to Cancer and Complex Therapies Act Issues related to most-favored-nation and other foreign reference drug pricing policy Issues related to the Food and Drug Administration Issues regarding 340B program Issues related to utilization management of medications
Discussions regarding H.R.946, the ORPHAN Cures Act Discussions related to H.R.2319, the Women and Lung Cancer Research and Preventative Services Act Discussions regarding H.R.4299,the Protecting Patient Access to Cancer and Complex Therapies Act Issues related to most-favored-nation and other foreign reference drug pricing policy Issues related to the Food and Drug Administration Issues regarding 340B program Issues related to utilization management of medications
Discussions regarding H.R.946, the ORPHAN Cures Act Discussions related to H.R.2319, the Women and Lung Cancer Research and Preventative Services Act Discussions related to the Protecting Patient Access to Cancer and Complex Therapies Act reintroduction Issues related to most-favored-nation and other foreign reference drug pricing policy Issues related to the Food and Drug Administration Issues regarding 340B program
Discussions regarding tax reform and tariffs
Issues related to intellectual property rights
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of
DAIICHI SANKYO INC via DAIICHI SANKYO, INC.
2026 · second_quarter · Q2
Discussions regarding H.R.946, the ORPHAN Cures Act Discussions related to H.R.2319, the Women and Lung Cancer Research and Preventative Services Act Discussions related to the Protecting Patient Access to Cancer and Complex Therapies Act reintroduction Issues related to most-favored-nation and other foreign reference drug pricing policy Issues related to the Food and Drug Administration Issues regarding 340B program
Issues related to the Medicare Drug Price Negotiation Program Issues regarding the GLOBE model
Discussions regarding tax reform and tariffs
Issues related to intellectual property rights
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of